Pulse Biosciences' PMA Timeline and Mapping System Use Spark Contradictions in 2026 Q2 Earnings Call

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $434,000 (from disposable sales of NPulse Vibrance system)

Business Commentary:

Cardiac Catheter Program Enrollment:

• Pulse Biosciences enrolled the first patient in their pivotal catheter IDE study and surpassed the halfway point with over 82 evaluable patients ahead of schedule, expecting completion in early Q4 2026.
• The rapid enrollment is attributed to physician enthusiasm and the intuitive, efficient workflow of the NSPFA technology, allowing for multiple cases per day.

Strategic Financial Strengthening:

• The company strengthened its balance sheet with over $100 million in cash, including $57.5 million in net proceeds from an ATM program, and an additional $13 million from insider support.
• This financial progress reflects external confidence in the NSPFA platform and its growth opportunities, enabling extended funding for clinical and regulatory milestones.

Surgical Clamp and Thyroid Programs:

• The surgical clamp program's EU feasibility study treated more than 70 patients, demonstrating high efficacy with a 94% pulmonary vein isolation success rate at three months.
• The thyroid program's Vibrance system saw a sequential increase in disposable sales to $434,000, supported by a new partnership with the Clayman Thyroid Center to expand clinical data and market reach.

Clinical Differentiation and Market Potential:

• NSPFA technology showed significant clinical differentiation with a 90% Kaplan-Meier estimated freedom from recurrent AF at one year in European feasibility data, compared to lower success rates with other ablation technologies.
• The technology's mechanism of regulated cell death, offering non-thermal ablation, is seen as a key driver for potential market disruption and adoption in treating atrial fibrillation.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed strong enthusiasm: 'amazing and novel technology,' 'positive and important achievements,' 'enrollment...ahead of our original schedule,' 'confidence in completing enrollment on our accelerated timeline,' 'remarkable clinical differentiation,' 'unprecedented potential to transform the treatment landscape.'

Q&A:

• Question from Bill Plavancic (Canaccord Genuity): Given the fast enrollment, does it benefit to combine 6- and 12-month data for the PMA submission, or wait for full 12-month data?
  Response: Focus is on 12-month follow-up for the first half patients; enrollment speed is the priority, and they will use all tools to manage timelines effectively.

• Question from Bill Plavancic (Canaccord Genuity): Are any sites being capped to maintain enrollment pace, and are learnings from the first 80 patients leading to protocol changes?
  Response: Sites are capped at 15% enrollment; several have already met their cap. The main learning is the extraordinary physician enthusiasm and positive acute experience with the catheter, indicating strong potential for adoption.

• Question from Anthony Patron (Mizuho Group): Is mapping integration with Carto still planned for the IDE, and what do continuous mapping studies show?
  Response: All IDE cases to date have been enrolled using NSITE mapping system; they expect tighter integration to improve procedure efficiency and outcomes but will not comment on protocol changes.

• Question from Anthony Patron (Mizuho Group): Does the recent capital raise contemplate building sales/marketing infrastructure for launch?
  Response: They will stay disciplined with cash, aiming for at least five quarters of runway. They are prepared for market development and have received calls from top sales/marketing professionals.

• Question from Siraj Khalia (Oppenheimer): Why was the AAD class expanded, and will the rest of the patients be on NSITE?
  Response: Expanded AAD classes to align with contemporary clinical practice; adding 19 patients strengthens statistical rigor without delaying enrollment. Remaining patients will be enrolled on NSITE, as has been the case.

• Question from Josh Jennings (Katie Cohen): Are physicians forecasting high procedure volumes per day with impulse AFib ablation, and how does efficacy compare to competitors?
  Response: Physicians are experiencing high throughput (e.g., 7 cases/day) due to efficiency; they believe NSPFA irreversibly kills cells, providing a differentiated efficacy profile that could drive market adoption.

Contradiction Point 1

Timeline Drivers for Data Submission

Different emphasis on primary timeline factors for PMA submission.

Bill Plavancic (Canaccord Genuity) - Bill Plavancic (Canaccord Genuity)

2026Q2: The timeline is primarily governed by the 12-month follow-up of the first enrolled patients. - Paul LaViolette(CEO)

Should we combine 6- and 12-month data from the nanopulse AF pivotal study for the final module submission, or wait for full 12-month data? - Bill Plovanic (Canaccord Genuity)

2026Q2: The key timeline driver is the 12-month follow-up for the first enrolled patients. - Paul LaViolette(CEO)

Contradiction Point 2

Site Enrollment Management and Momentum

Contradiction on whether site caps are a pacing mechanism or a regulatory requirement.

Bill Plavancic (Canaccord Genuity) - Bill Plavancic (Canaccord Genuity)

2026Q2: Yes, the FDA protocol includes a cap of 15% of total enrollment per site... to ensure a representative patient pool. - Paul LaViolette(CEO)

Are sites stopping due to high patient enrollment maintaining the enrollment timeline despite the study expansion? - Bill Plovanic (Canaccord Genuity)

2026Q2: Yes, there is an FDA-mandated cap of 15% of total enrollment per site. Several sites have already reached this cap. The momentum is regulated by the turnover of high-performing sites reaching their limit and new sites activating... - Paul LaViolette(CEO)

Contradiction Point 3

Mapping System Utilization in the U.S. Pivotal Study

Conflicting statements on whether only Abbott's NSITE system will be used.

Anthony Patron (Mizuho Group) - Anthony Patron (Mizuho Group)

2026Q2: To date, all cases in the IDE have been performed using the NSITE mapping system. Physician discussions suggest that tighter integration of the catheter on mapping systems could further improve procedural efficiency... The IDE allows for use of any commercial mapping system, but no changes have been implemented yet. - Paul LaViolette(CEO)

In the nanopulse AF pivotal IDE study, are you still using Abbott's NSITE mapping system or have you integrated Carto, and how might continuous mapping impact results compared to the feasibility study using only fluoroscopy? - Anthony Petrone (Mizuho)

2026Q1: EnSite is expected to be the predominant, and likely the only, mapping system used in the U.S. pivotal trial due to enrollment speed and availability... - Paul LaViolette(CEO)

Contradiction Point 4

Timing for Enrolling and Completing the Nanopulse AF Pivotal Study

The projected timeline for trial completion appears to have shifted forward.

Bill Plavancic (Canaccord Genuity) - Bill Plavancic (Canaccord Genuity)

2026Q2: The focus is on... maintaining enrollment quality and velocity... The enrollment pace is exceptionally strong... sites already reaching their 15% enrollment cap. - Paul LaViolette(CEO)

"With rapid enrollment in the nanopulse AF pivotal study, should you combine 6- and 12-month data for the final module submission or wait for full 12-month data?" - Anthony Petrone (Mizuho Group)

20260220-2025 Q4: Enrollment for the nPulse cardiac catheter IDE study is expected to commence in the next 1-2 months, with completion planned for 2026. - Paul LaViolette(CEO)